Tradestie Institutional Equity Comparison Engine
ATYR vs ENTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (1โ1 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Options & Structure while ATYR counters with relative strength in Momentum & Technical. Fundamentally, ATYR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ATYR N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
ATYR
1Y +558.7% vs +11.6% ยท 52W Pos 62% vs 64%
Options & Structure Winner
ENTX
UNCLASSIFIED (36th %ile IV) vs CONSOLIDATION (32nd %ile IV)
ATYR
NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap
$15.6M
1M Return
+2788.76%
1Y Return
+558.7%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
+0.17% 1D
Market Cap
$541.6M
1M Return
+2.89%
1Y Return
+11.62%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ATYR +558.7%
ENTX +11.62%
Spread: +547.08 pp (ATYR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | ENTX Revenue | ATYR Op. Margin | ENTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -5445.0% | N/A | ATYR |
| FY2020 | $10M | $0M | -152.2% | -3059.7% | ATYR |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | $10M | $0M | -446.8% | -9714.2% | ATYR |
| FY2023 | $0M | N/A | -15557.8% | N/A | ATYR |
| FY2024 | $0M | $0M | -28899.6% | -5295.6% | ENTX |
| FY2025 | $0M | $0M | -40856.3% | -27450.0% | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ATYR | ENTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.6M | $541.6M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | ATYR |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -93.7% | -20.3% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 62% ($0โ$8) | 64% ($1โ$4) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | -9.67ฮฒ ยท 13806% Vol | 1.07ฮฒ ยท 46% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 53.5 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ATYR vs ENTX Buy Guide
ATYR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
36th %ile
IV Regime
Balanced (25thโ60th %ile)
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ATYR nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.